Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
A legfontosabb adatok
- Ki végzi
- Samer Gawrieh
- Hol
- Cleveland, Dallas, Indianapolis, Louisville, Richmond és Rochester (Egyesült Államok)Mind a 6 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 216 fő, tervezett
- Kezdés
- 2026. jan. 27.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- IL-22
- Prednisone
- Acamprosate
- Prednisone placebo
- IL-22 (F-652) Placebo
- Motivational Interviewing (MI)
- Motivational Enhancement Therapy (MET)
- Usual Care
- A regiszteradat frissítve
- 2026. július 15.
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18, <70
- MELD 20-35
- Definitive or probable diagnosis of sAH as defined by the NIAAA criteria4, 5 A. Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the prior 8 weeks B. Ongoing average consumption of > 40 gm (for females) and > 60 gm (for males) alcohol daily for 6 months or more with less than 8 weeks of abstinence before onset of jaundice; OR If, in the investigator's judgment, alcohol use may have been underreported, available clinical evidence-including collateral history, medical records, prior documentation of alcohol use, alcohol biomarkers such as PEth, or other relevant evidence-indicates that the participant met the protocol-defined alcohol consumption requirement within the 8 weeks before screening; AST > 50 IU/L, D. AST: ALT > 1.5 E. ALT and AST values < 400 IU/L F. Liver biopsy findings consistent with AH; *In patients with possible AH or AH with confounding factors such as possible ischemic hepatitis, possible DILI, uncertain history of alcohol use (e.g., patient denies excessive alcohol use), and atypical/abnormal laboratory tests (e.g., AST < 50 IU/L or > 400 IU/L, AST/ALT ratio < 1.5), antinuclear antibody > 1:160 or SMA > 1:80, a standard of care liver biopsy will be considered during current hospital admission to confirm AH and exclude competing etiologies
- Females of childbearing (reproductive) potential must have a negative serum or urine pregnancy test at screening
Ki nem vehet részt
- Active listing for liver transplantation before screening
- Prior exposure to systemic corticosteroid (glucocorticoid) or TNF-alpha inhibitors for more than 4 days within the previous 30 days prior to screening, specifically for the treatment of sAH
- Significant concomitant medical illnesses (such as uncontrolled congestive heart failure or COPD or progressive multi-organ failure) as determined by the study investigator
- Uncontrolled HBV, HIV, or HCV infection with persistent viremia. However, subjects with controlled (undetectable viral load) HIV and HBV on viral suppressive therapies will be enrolled and subjects with history of HCV will be enrolled if they have evidence of SVR within one year prior to enrollment
- Unwillingness to either abstain from sexual intercourse, or if sexually active, use a reliable method of birth control during the study and for at least 30 days after the last dose of the study medication. Examples of acceptable birth control methods include double barrier method such as condom and occlusive cap (diaphragm or cervical cap) with spermicidal foam/gel/film/cream/suppository; birth control pills, patches, injections, or implants; intrauterine device (IUD); vasectomy and tubal ligation
- Uncontrolled infection (persistent positive blood or other body fluid cultures despite 48 hours of antibiotic therapy)
- Clinically active C. diff infection
- Evidence of other liver diseases (such as autoimmune hepatitis, primary biliary cholangiopathy, primary sclerosing cholangitis, ischemic, sepsis- or drug-induced liver disease)
- History or presence of cancer (including hepatocellular carcinoma) other than non-melanoma skin cancer
- Uncontrolled mental illness as determined by the study investigator
- Uncontrolled diabetes mellitus with A1c > 9
- Known allergy or intolerance to therapeutic agents to be tested
- Participant has any condition or circumstance that adversely affects the participant, could cause noncompliance with treatment or visits, may impact the interpretation of clinical data, could cause bias, or may otherwise contraindicate the participant's participation in the study
- Renal failure defined by estimated GFR (CKD-EPI) <35 mL/min
- Clinically significant pancreatitis- abdominal pain, elevated lipase (> 3 X ULN), and at least edema of pancreas with fat-stranding on CT scan
- Active gastrointestinal bleeding defined as hematemesis or melena with a decrease in hemoglobin more than 2 g/dl in 24 hours due to gastrointestinal bleeding, or with a decrease in mean arterial BP to < 65 mmHg
- MELD score <20 or > 35
- Progressive hemodynamic compromise requiring intravenous pressors
- Pneumonia as evidenced by clinical and/or radiological examination (will not perform radiology if not indicated by clinical exam)
- Active illicit opiates, cocaine, ketamine, or methamphetamine use in the last 30 days via patient report or medical chart review
- Pregnancy or breastfeeding
- Unwillingness to stop alcohol use and to undergo AUD treatment
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Cleveland ClinicCleveland, Egyesült ÁllamokContact: Srinivasan Dasarathy, MD (principal investigator)Résztvevőt keres
- University of Texas Southwestern Medical SchoolDallas, Egyesült ÁllamokContact: Mack Mitchell, MD (principal investigator)Résztvevőt keres
- Indiana UniversityIndianapolis, Egyesült ÁllamokContact: Raj Vuppalanchi, MD (principal investigator)Résztvevőt keres
- University of LouisvilleLouisville, Egyesült ÁllamokContact: Ashwani Singal, MD (principal investigator)Résztvevőt keres
- Virginia Commonwealth UniversityRichmond, Egyesült ÁllamokContact: Arun Sanyal, MD (principal investigator)Résztvevőt keres
- Mayo ClinicRochester, Egyesült ÁllamokContact: Vijay Shah, MD (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
A teljes eredeti leírásKevesebb
The primary purpose of the study is to determine whether subjects receiving sAH therapy in addition to AUD treatments will have better alcohol and liver-related outcomes at 6 months compared to sAH therapy plus usual care for AUD. Patients assigned to the AUD treatment will receive Acamprosate and counseling whereas those assigned to AUD standard care will receive brief advice and referral to a 12-step program.
The secondary purpose of the study is to determine if F-652 is safe and effective in treating sAH when compared to prednisone. Subjects will receive F-652 on days 1 and 7 or prednisone for 28 days. Outcomes will be measured by overall survival at 90 days.
A vizsgálat 4 csoportja
- IL-22 (F-652), Prednisone Placebo, Acamprosate, MI and METMár használt kezelés, összehasonlításként
F-652 on days 1 and 7 and matching placebos for prednisone for 28 days and acamprosate for 6 months. MI will be delivered during the hospitalization; MET sessions will be delivered in the first 3 months
Kezelés: IL-22, Acamprosate, Prednisone placebo, Motivational Interviewing (MI) és Motivational Enhancement Therapy (MET)
- IL-22 (F-652), Prednisone Placebo, and usual careMár használt kezelés, összehasonlításként
F-652 on days 1 and 7 and matching placebo for prednisone for 28 days and usual care for AUD.
Kezelés: IL-22, Prednisone placebo és Usual Care
- Prednisone, IL-22 (F-652) Placebo, Acamprosate, MI, and METMár használt kezelés, összehasonlításként
Prednisone for 28 days and matching placebos for F-652 on days 1 and 7 and acamprosate for 6 months. MI will be delivered during the hospitalization; MET sessions will be delivered in the first 3 months
Kezelés: Prednisone, Acamprosate, IL-22 (F-652) Placebo, Motivational Interviewing (MI) és Motivational Enhancement Therapy (MET)
- Prednisone, IL-22 (F-652) Placebo, and usual careMár használt kezelés, összehasonlításként
Prednisone for 28 days and matching placebo for F-652 on days 1 and 7 and usual care for AUD.
Kezelés: Prednisone, IL-22 (F-652) Placebo és Usual Care
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Kérdések a feltételekről
- Forrás: NCT07060638: ki vehet részt
- A regiszteradat frissítve
- 2026. július 15.